51 studies found for:    NIAID | Open Studies | Exclude Unknown
Show Display Options
Rank Status Study
21 Not yet recruiting Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA Nat-B env vaccine;   Biological: NYVAC Nat-B env vaccine;   Biological: DNA CON-S env vaccine;   Biological: NYVAC CON-S env vaccine;   Biological: DNA Mosaic env vaccine;   Biological: NYVAC Mosaic env vaccine;   Biological: Placebo;   Device: Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)
22 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV cps2 Vaccine;   Biological: Placebo Vaccine
23 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV cps2 Vaccine;   Biological: Placebo Vaccine
24 Not yet recruiting Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID ΔM2-2 Vaccine;   Biological: Placebo Vaccine
25 Recruiting Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV MEDI ΔM2-2 vaccine;   Biological: Placebo vaccine
26 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine;   Biological: Placebo (1x Leibovitz L-15 medium)
27 Recruiting Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3
Condition: Shigella Infection
Interventions: Biological: WRSs3;   Other: Placebo;   Biological: WRSs2
28 Recruiting Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart
Condition: Dengue
Interventions: Biological: TV003 Vaccine;   Biological: Placebo Vaccine
29 Recruiting Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
Condition: Dengue
Interventions: Biological: TetraVax-DV-TV003;   Biological: rDEN2∆30-7169;   Biological: Placebo
30 Recruiting Staged Phase I/II Hepatitis C Prophylactic Vaccine
Condition: Hepatitis C
Interventions: Biological: AdCh3NSmut1;   Other: Placebo;   Biological: MVA-NSmut
31 Recruiting Screening Volunteers for Clinical Trials
Condition: Human Volunteers
Intervention:
32 Not yet recruiting H7N9 Mix and Match With MF59 in Healthy Elderly Persons
Condition: Avian Influenza
Interventions: Biological: MF59;   Biological: A/H7N9 influenza virus vaccine
33 Not yet recruiting Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: NYVAC-HIV-PT1 vaccine;   Biological: NYVAC-HIV-PT4 vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo for DNA/NYVAC/AIDSVAX
34 Recruiting Phase I STEBVax in Healthy Adults
Condition: Toxic Shock Syndrome Staphylococcal
Intervention: Biological: STEBVax
35 Not yet recruiting Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123;   Biological: NYVAC-HIV-PT1;   Biological: NYVAC-HIV-PT4;   Biological: AIDSVAX B/E®;   Biological: Placebo vaccine
36 Recruiting Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: AIDSVAX B/E Vaccine;   Biological: DNA-HIV-PT123 Vaccine;   Biological: Placebo for DNA-HIV-PT123;   Biological: Placebo for AIDSVAX B/E
37 Recruiting Collection of Biological Material From Pregnant Women in a Malarial Region
Condition: Malaria
Intervention:
38 Recruiting Systems Biology of 23-valent Pneumococcal Polysaccharide Vaccine (PNEUMOVAX®23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®)
Condition: Pneumococcal Infection
Interventions: Biological: PNEUMOVAX and PREVNAR;   Biological: Pneumovax or Prevnar
39 Not yet recruiting Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
Conditions: HIV;   Pneumococcal Infections;   Pneumococcal Vaccines
Interventions: Biological: PCV-13;   Biological: PPSV-23
40 Recruiting Immune Memory After Papillomavirus Vaccination
Condition: Healthy Volunteers
Intervention: Drug: quadrivalent HPV vaccine

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-51) Show next page of results
Indicates status has not been verified in more than two years